SWOG clinical trial number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Closed
Phase
Abbreviated Title
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status Notes
Closed to accrual as of 10/2/2023.
Activated
05/01/2021
Closed
10/02/2023
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin 5-Fluorouracil Carboplatin Doxorubicin Gemcitabine hydrochloride Methotrexate Mitomycin-C Vinblastine Sulfate durvalumab

Eligibility Criteria Expand/Collapse

Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (https://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2022

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration

M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

2021

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN & NRG Collaboration

M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci J Clin Oncol 39, 2021 (suppl 15; abstr TPS4590) (American Society of Clinical Oncology Annual Meeting 2021, poster session)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase